deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT03110562

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Sponsor: Karyopharm Therapeutics Inc

Conditions Multiple Myeloma
Interventions Bortezomib Dexamethasone Selinexor
Updated 33 times since 2017 Last updated: Jul 25, 2024 Started: May 24, 2017 Primary completion: Feb 18, 2020 Completion: May 12, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Multiple Myeloma and is currently completed. Karyopharm Therapeutics Inc leads this study, which shows 33 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jun 2019 · 6 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Feb 2023 · 14 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 8 months · monthly snapshot

Change History

33 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Jan 2026 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 28 earlier versions

  1. Dec 2021 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Oct 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  8. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Mar 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  12. Oct 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  13. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  14. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  15. Dec 2018 — Jun 2019 [monthly]

    Recruiting PHASE3

  16. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  17. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  18. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  19. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  20. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  21. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  22. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE3

  23. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  24. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE3

  25. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  26. Jul 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  27. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  28. May 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Karyopharm Therapeutics Inc
Data source: Karyopharm Therapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ames, United States , Ancona, Italy , Anderson, United States , Ashkelon, Israel , Athens, Greece , Atlanta, United States , Badalona, Spain , Baltimore, United States , Barcelona, Spain and 121 more locations